Evolution of Systemic Therapy for Hepatocellular Carcinoma
Richard S. Finn, Andrew X. Zhu
Abstract
Despite being one of the leading causes of cancer death globally, hepatocellular carcinoma (HCC) has historically not been the focus of novel drug development. That has changed in the past several years, with the results from a number of hallmark phase 3 studies in advanced HCC. In HCC, immune-oncology approaches have garnered much attention; there is still a need to better understand criteria for patient selection and to optimize combination strategies to maximize the potential of these approaches. The next generation of studies will aim at translating our increased understanding of tumor biology into clinical trial design.
Topics & Concepts
Hepatocellular carcinomaMedicineSystemic therapyOncologyClinical trialDrug developmentIntensive care medicineCancerSelection (genetic algorithm)Internal medicineDrugPharmacologyComputer scienceArtificial intelligenceBreast cancerHepatocellular Carcinoma Treatment and PrognosisLiver physiology and pathologyCancer, Hypoxia, and Metabolism